Neonatal Drug Therapy Manual

Sulfamethoxazole/Trimethoprim

Disclaimer: Official controlled document is the CHEO and Ottawa Hospital online copy. It is the responsibility of user to ensure that any paper copy version is the same as the online version before use.

Alternate Name(s): 
Cotrimoxazole, Septra
Classification: 
Antibiotic
Original Date: 
January 2009
Revised Date: 
January 2018
Indications: 
  • Treatment of infections caused by Stenotrophomonas maltophilia, unresponsive to other therapies.
Administration: 
  • IV intermittent infusion: over 60 minutes
  • PO
Dosage: 

Dosage recommendations are based on the trimethoprim component

IV/PO:

  • 15 - 20 mg/kg/day divided Q6-8h

Dosage adjustment required in renal impairment. Refer to available references or clinical pharmacist for dosage adjustment

Side Effects: 
  • Dermatologic: skin rash, Stevens-Johnson (rare)
  • Endocrine and metabolic: hyperkalemia, hypoglycemia (rare), hyponatremia
  • GI: nausea and vomiting
  • Hematologic: anemia, eosinophilia, leukopenia, neutropenia, thrombocytopenia
  • Hepatic: cholestatic jaundice, hyperbilirubinemia, increased transaminases
  • Local: irritation, pain, phlebitis
  • Renal: increased blood urea nitrogen, increased serum creatinine
Parameters to Monitor: 
  • CBC
  • Electrolytes
  • BUN, creatinine
  • Bilirubin
Reconstitution and Stability: 
  • Sulfamethoxazole 80 mg/mL and Trimethoprim 16 mg/mL
    • Take 2.5 mL (40 mg of Trimethoprim) and add to 47.5 mL of D5W
    • Final concentration: 0.8 mg/mL of Trimethoprim
Compatibility: 
  • Solutions Compatible: D5W
  • Incompatible: dobutamine, fentanyl, midazolam, 0.9% NaCL
  • Uncertain: TPN

-Variable compatibility periods have been reported for sulfamethoxazole-trimethoprim mixed in solutions. Precipitation of trimethoprim occurs irregularly in varying time periods depending on the concentration, with more rapid precipitation being possible at higher concentrations. The specific solution may also influence the precipitation. For all mixtures involving sulfamethoxazole-trimethoprim, including Y-site administration, careful inspection and close monitoring for precipitation is warranted.

Notes: 
  • Avoid in infants < 1 month of age
  • Contains benzyl alcohol
References: 
  • Lexicomp (Lexi-Drugs), Drug Information Handbook 23rd Ed. Hudson, Ohio, Lexi-Comp, Inc. 2014-2015
  • Chen.J, Lau.E (Editors), Drug handbook and Formulary - The Hospital for Sick Children. Toronto; 2017
  • Ryan KL, Dersch-Mills D, Clark D. Trimethoprim-Sulfamethoxazole for Treatment of Stenotrophomonas maltophilia Pneumonia in a Neonate. Can J Hosp Pharm. 2013 Nov;66(6):384-7.

The information contained on this website is provided for informational purposes only, as a guide to assist physicians, nurses and other healthcare providers in deciding on the appropriate care required for a particular patient. At all times, physicians, nurses and other healthcare providers must exercise their independent clinical judgment, based on their knowledge, training and experience, taking into account the specific facts and circumstances of each patient, when deciding on the appropriate course of investigation and/or treatment to recommend in a particular clinical situation.

CHEO has made every effort to ensure that the information contained on this website is as current and accurate as possible. However, changes can occur due to ongoing research and the constant influx of new information. Where possible, hospitals and healthcare practitioners should verify the information before acting on it.

Reliance on any information in this website is at the user's own risk. CHEO is not responsible or liable for any harm, loss or other consequences from the use or misuse of the information on this website.